{"id":412808,"date":"2021-01-12T07:03:40","date_gmt":"2021-01-12T12:03:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412808"},"modified":"2021-01-12T07:03:40","modified_gmt":"2021-01-12T12:03:40","slug":"la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/","title":{"rendered":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe"},"content":{"rendered":"

<\/p>\n

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe<\/b><\/p>\n

La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments<\/i><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–La Jolla Pharmaceutical Company<\/a> (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA\u2122 (angiotensin II) and XERAVA\u2122 (eravacycline) in the European Economic Area, the United Kingdom and Switzerland (the Territories).\n<\/p>\n

\nUnder the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.\n<\/p>\n

\nGIAPREZA is approved by the European Commission as a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. XERAVA is approved by the European Commission for the treatment of complicated intra-abdominal infections in adults.\n<\/p>\n

\n\u201cOur agreement with PAION marks an important step in our global strategic plans to bring innovative therapies that improve outcomes in patients suffering from life-threatening diseases to Europe,\u201d said Larry Edwards, President and Chief Executive Officer of La Jolla. \u201cWe are excited to have PAION as a partner and expect its commercialization expertise will be invaluable in maximizing the value of GIAPREZA and XERAVA in Europe.\u201d\n<\/p>\n

\n\u201cWe are excited to add these attractive hospital products to our portfolio, giving us a strong basis to launch our European commercial organization and to build out our sales and marketing activities,\u201d said Dr. Jim Phillips, Chief Executive Officer of PAION AG. \u201cWe will be using single, hospital focused sales teams in each country to commercialize these products in Europe. The licensing agreement announced today puts us on strong footing to become a leading specialty pharmaceutical company in the fields of anaesthesia and critical care.\u201d\n<\/p>\n

About GIAPREZA<\/b><\/p>\n

\nGIAPREZA\u2122 (angiotensin II) for injection is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body\u2019s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at http:\/\/www.giapreza.com<\/a>. The European Summary of Product Characteristics is available on the EMA website: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/giapreza<\/a>. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and will be marketed in Europe by PAION AG on behalf of La Jolla Pharma, LLC.\n<\/p>\n

GIAPREZA Important Safety Information<\/b><\/p>\n

Contraindications<\/b><\/p>\n

\nNone.\n<\/p>\n

Warnings and Precautions<\/b><\/p>\n

\nThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.\n<\/p>\n

Adverse Reactions<\/b><\/p>\n

\nThe most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.\n<\/p>\n

Drug Interactions<\/b><\/p>\n

\nAngiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.\n<\/p>\n

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov\/medwatch<\/a> or call 1-800-FDA-1088.<\/b><\/p>\n

For additional information, please see Full Prescribing Information<\/a> for the United States and the Summary of Product Characteristics<\/a> for the European Union.<\/b><\/p>\n

About XERAVA<\/b><\/p>\n

\nXERAVA\u2122 (eravacycline) for injection is a novel fluorocycline of the tetracycline class of antibacterials that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA is approved by the European Commission (EC) for the treatment of cIAI in adults. Prescribing information for XERAVA is available at www.xerava.com<\/a><\/span>. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and will be marketed in Europe by PAION AG on behalf of Tetraphase Pharmaceuticals, Inc.\n<\/p>\n

XERAVA Important Safety Information<\/strong><\/p>\n

\nXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.\n<\/p>\n

\nXERAVA is not indicated for the treatment of complicated urinary tract infections.\n<\/p>\n

\nTo reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.\n<\/p>\n

\nXERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.\n<\/p>\n

\nThe use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.\n<\/p>\n

\nThe use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.\n<\/p>\n

\nClostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.\n<\/p>\n

\nThe most common adverse reactions observed in clinical trials (incidence \u2265 3%) were infusion site reactions, nausea and vomiting.\n<\/p>\n

\nXERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.\n<\/p>\n

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov\/medwatch<\/a> or call 1-800-FDA-1088.<\/b><\/p>\n

For additional information, please see Full Prescribing Information<\/a> for the United States.<\/b><\/p>\n

About La Jolla Pharmaceutical Company<\/b><\/p>\n

\nLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA\u2122 (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA\u2122 (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit www.ljpc.com<\/a>.\n<\/p>\n

Forward-looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA\u2122 (angiotensin II) and XERAVA\u2122 (eravacycline) sales; regulatory actions relating to La Jolla\u2019s products by the U.S. FDA, European Commission and\/or other regulatory authorities; the expected future cash flows, including any upfront, milestone and\/or royalty payments, resulting from La Jolla\u2019s exclusive license agreement with PAION AG and its wholly owned subsidiary; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210112005460\/en\/<\/a><\/span><\/p>\n

\nMichael Hearne
\n
Chief Financial Officer
\n
La Jolla Pharmaceutical Company
\n
(858) 333-5769
\n
mhearne@ljpc.com<\/a><\/p>\n

KEYWORDS:<\/b> North America United States United Kingdom Switzerland Europe California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Health Pharmaceutical Cardiology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA\u2122 (angiotensin II) and XERAVA\u2122 (eravacycline) in the European Economic Area, the United Kingdom and Switzerland (the Territories). Under … <\/p>\n

Continue reading “La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412808","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA\u2122 (angiotensin II) and XERAVA\u2122 (eravacycline) in the European Economic Area, the United Kingdom and Switzerland (the Territories). Under … Continue reading "La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T12:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe\",\"datePublished\":\"2021-01-12T12:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/\"},\"wordCount\":1397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/\",\"name\":\"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-12T12:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk","og_description":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA\u2122 (angiotensin II) and XERAVA\u2122 (eravacycline) in the European Economic Area, the United Kingdom and Switzerland (the Territories). Under … Continue reading \"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T12:03:40+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe","datePublished":"2021-01-12T12:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/"},"wordCount":1397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/","name":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-12T12:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005460r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/la-jolla-pharmaceutical-company-announces-exclusive-licensing-agreement-for-giapreza-angiotensin-ii-and-xerava-eravacycline-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412808"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412808\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}